Pain management

Muscle Stimulator Market Projected to Reach $925.48 million by 2030 - Exclusive Report by 360iResearch

Retrieved on: 
Friday, May 3, 2024
TENS, Pain, Brain, Lactic acid, Inflammation, Stroke, Mobile device, Investment, EMS, Acceleration, Functional electrical stimulation, Hope, Sport, MENS, Traction, Table, System, Omron, Intelligence, Injury, Nerve, Pain management, BMAC, Optimism, Physical fitness, Electrical muscle stimulation, NMES, Movement, Athlete, Regeneration, Tetraplegia, Quality of life, Growth, Medical device

However, the muscle stimulator market does face hurdles, including stringent regulatory measures and competition from other therapeutic modalities and fitness equipment.

Key Points: 
  • However, the muscle stimulator market does face hurdles, including stringent regulatory measures and competition from other therapeutic modalities and fitness equipment.
  • This market scenario highlights a collective movement toward embracing muscle stimulator technologies for enhanced physical well-being and recovery.
  • We proudly unveil ThinkMi, a cutting-edge AI product designed to transform how businesses interact with the Muscle Stimulator Market.
  • "Dive into the Muscle Stimulator Market Landscape: Explore 194 Pages of Insights, 922 Tables, and 26 Figures"

Muscle Stimulator Market Projected to Reach $925.48 million by 2030 - Exclusive Report by 360iResearch

Retrieved on: 
Friday, May 3, 2024
TENS, Pain, Brain, Lactic acid, Inflammation, Stroke, Mobile device, Investment, EMS, Acceleration, Functional electrical stimulation, Hope, Sport, MENS, Traction, Table, System, Omron, Intelligence, Injury, Nerve, Pain management, BMAC, Optimism, Physical fitness, Electrical muscle stimulation, NMES, Movement, Athlete, Regeneration, Tetraplegia, Quality of life, Growth, Medical device

However, the muscle stimulator market does face hurdles, including stringent regulatory measures and competition from other therapeutic modalities and fitness equipment.

Key Points: 
  • However, the muscle stimulator market does face hurdles, including stringent regulatory measures and competition from other therapeutic modalities and fitness equipment.
  • This market scenario highlights a collective movement toward embracing muscle stimulator technologies for enhanced physical well-being and recovery.
  • We proudly unveil ThinkMi, a cutting-edge AI product designed to transform how businesses interact with the Muscle Stimulator Market.
  • "Dive into the Muscle Stimulator Market Landscape: Explore 194 Pages of Insights, 922 Tables, and 26 Figures"

Nura Pain Clinics Announces New Edina Clinic Renovations to Optimize Patient Care

Retrieved on: 
Thursday, May 2, 2024
Capitol, Pain, Health, Pain management, Patient, Investment, Chronic pain, Nura, Birth control

EDINA, Minn., May 2, 2024 /PRNewswire/ -- Nura Pain Clinics, a subsidiary of the Capitol Pain family of practices, proudly announce the completion of a remodel to its Edina clinic located at 7400 France Avenue South. The renovation includes dedicating an additional 3,500 square feet of existing space to its surgery center, enhancing patient care capabilities.

Key Points: 
  • EDINA, Minn., May 2, 2024 /PRNewswire/ -- Nura Pain Clinics , a subsidiary of the Capitol Pain family of practices, proudly announce the completion of a remodel to its Edina clinic located at 7400 France Avenue South.
  • "This remodel allows us to see more patients as efficiently as possible, ensuring they get timely access to the care they need," said Dr. David Schultz, chief medical officer of Nura Pain Clinics.
  • Nura, Minnesota's foremost multidisciplinary pain management practice, continues to see an increased demand for its pain management services.
  • For more information on Nura Pain Clinics and its focus on pain management, visit nuraclinics.com .

EQS-News: Lindis Blood Care Announces Positive Top-Line Results from Clinical Certification Study REMOVE with CATUVAB® to Enable Autologous Blood Transfusions in Cancer Surgeries

Retrieved on: 
Friday, May 3, 2024
FDA, Cancer, Prostate, Cell, Risk, Blood, Filter, CE marking, Cytokine, Trauma, Immunosuppression, Intensive care medicine, MD, Carcinoma, PILOT, Pain management, Patient, Lung, Teaching hospital, Clinical trial, IBS, Medical imaging

Convincing safety profile supports use of CATUVAB® during high blood loss cancer surgeries.

Key Points: 
  • Convincing safety profile supports use of CATUVAB® during high blood loss cancer surgeries.
  • Following these positive results, Company has initiated process to receive CE Mark in Europe and FDA conformity in the US.
  • Lindis Blood Care, a company aiming to set a new standard for blood management during cancer surgeries with its medical device CATUVAB®, announced today excellent top-line results from the REMOVE certification study, a confirmatory open-label, multicenter clinical study, that enrolled more than 130 patients to assess CATUVAB® for use during intraoperative blood salvage (IBS) procedures in cancer surgeries.
  • CATUVAB® is designed to reliably remove cells from EpCAM (epithelial cell adhesion molecule)-positive tumors from the blood of cancer patients.

EQS-News: Lindis Blood Care to Present Top Line Results from Clinical Certification Study REMOVE with CATUVAB® at NATA24 Annual Symposium

Retrieved on: 
Friday, May 3, 2024
Cancer, Safety, Blood, Immunosuppression, Intensive care medicine, Pain management, Patient, Teaching hospital, Lymphocyte, IBS, Medical device

Lindis Blood Care, a company aiming to set a new standard for blood management during cancer surgeries with its medical device CATUVAB®, today announces that top line results of its certification study REMOVE assessing the Company’s medical device for the removal of tumor cells from intraoperative blood during high-blood loss surgeries will be presented at the NATA24 Annual Symposium.

Key Points: 
  • Lindis Blood Care, a company aiming to set a new standard for blood management during cancer surgeries with its medical device CATUVAB®, today announces that top line results of its certification study REMOVE assessing the Company’s medical device for the removal of tumor cells from intraoperative blood during high-blood loss surgeries will be presented at the NATA24 Annual Symposium.
  • The symposium will take place in Bologna, Italy between April 18 – 20, 2024.
  • CATUVAB® aims to ensure that cancer patients receive their own blood, minimizing the risks associated with allogenic (donor) blood transfusions.
  • Following the positive study outcome, CATUVAB® is aimed for approval in the EU and US in accordance with Medical Device Regulations.

Autonomix Enters into Agreement with NoiseFigure Research, Inc. to Develop Next Generation of its Proprietary Microchip

Retrieved on: 
Thursday, April 25, 2024
Collateral damage, Pain, NFR, AMIX, Intelligence, Disease, Nervous system, Application-specific integrated circuit, Pain management, ASIC, Ethanol, Medical imaging

As part of the agreement, Autonomix will work with NFR to assess its ASIC microchip and upgrade the chip to its second-generation in preparation for human clinical testing in the Company’s planned pivotal trial in 2025.

Key Points: 
  • As part of the agreement, Autonomix will work with NFR to assess its ASIC microchip and upgrade the chip to its second-generation in preparation for human clinical testing in the Company’s planned pivotal trial in 2025.
  • Additionally, NFR will evaluate a subsequent version meant to enable commercial production volumes.
  • Lori Bisson, Chief Executive Officer of Autonomix said, “This collaboration with NFR is an important step in the evolution of our technology and simple approach to a procedure for pain management and other indications.
  • Current approaches, primarily relying on opioids or invasive ethanol injections, can provide only limited relief and may lead to risky side effects.

36% OF MARIJUANA USERS REPORT REDUCED ALCOHOL CONSUMPTION SINCE USING CANNABIS PRODUCTS, NUMERATOR REPORTS

Retrieved on: 
Thursday, April 18, 2024
Snack, Energy, Taco Bell, Uber Eats, Consumer, THC, Candy, Sport, Beer, Little Caesars, Baby boomers, Dominoes, Pizza Hut, Gen, Generation Z, Friends, Box, Cannabis, Pain management, Popeyes, Music, Creativity, Fraction, Drink, Sleep, Drug

Overall, cannabis user profiles vary significantly based on substance type, with THC / marijuana users skewing younger and using cannabis on a more regular basis than CBD-only users, who tend to be older and less frequent users.

Key Points: 
  • Overall, cannabis user profiles vary significantly based on substance type, with THC / marijuana users skewing younger and using cannabis on a more regular basis than CBD-only users, who tend to be older and less frequent users.
  • THC usage impacts alcohol consumption, and more frequent users spend less than infrequent users on alcohol.
  • More than 1 in 3 THC users (36%) say they have reduced their alcohol consumption since they began using cannabis products — yet they are still more likely than non-users to buy alcohol (73% vs. 65%).
  • Daily THC users spend 15.3% of their grocery dollars on alcohol, infrequent users spend 18.1%, and non-users spend 14.3%.

Virpax Announces Results of Maximum Tolerated Dose Study for Probudur™

Retrieved on: 
Tuesday, April 30, 2024
Research, Medical Devices, Surgery, Infectious Diseases, Clinical Trials, Biotechnology, Pharmaceutical, Health, Science, Other Science, Pain, Brain, Rat, Liposome, Post-traumatic stress disorder, Hematology, Animal, Bupivacaine, Human, IND, CNS, MTD, Pain management, Maxima and minima, Central nervous system, Index, Pharmaceutical industry

Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ: VRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and anti-viral barrier indications, today announced results for a Maximum Tolerated Dose (MTD) study in Sprague-Dawley Rats for Probudur™.

Key Points: 
  • Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ: VRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and anti-viral barrier indications, today announced results for a Maximum Tolerated Dose (MTD) study in Sprague-Dawley Rats for Probudur™.
  • Probudur is being developed to significantly reduce or eliminate the need for opioids after surgery in approved indications.
  • Probudur is a local anesthetic that binds to the sodium channel, preventing pain signals from reaching the brain.
  • The study was designed to determine the MTD of free bupivacaine, Probudur, and Probudur plus free bupivacaine when administered as a single subcutaneous injection to the wound.

Renowned Functional Medicine and Anti-Aging Practice Announces Expansion

Retrieved on: 
Tuesday, April 30, 2024
Pain, Acupuncture, Health, Human, PRP, Hair loss, Pain management, Patient, Headache, Medicine, Trust, Regenerative medicine, Toxicity, Beauty, Ageing, Longevity, Injection, Medical imaging

NEW YORK, April 30, 2024 /PRNewswire-PRWeb/ -- Dr. Alexander Golberg, board-certified in family medicine, osteopathic, anti-aging, and regenerative medicine, is proud to announce the opening of a new flagship location at 910 Park Avenue in Manhattan. Dr. Golberg established his practice in Brooklyn 25 years ago and is renowned for his natural, whole-person approach to pain management and anti-aging rooted in the philosophies of functional medicine.

Key Points: 
  • NEW YORK, April 30, 2024 /PRNewswire-PRWeb/ -- Dr. Alexander Golberg, board-certified in family medicine, osteopathic, anti-aging, and regenerative medicine, is proud to announce the opening of a new flagship location at 910 Park Avenue in Manhattan.
  • Dr. Golberg established his practice in Brooklyn 25 years ago and is renowned for his natural, whole-person approach to pain management and anti-aging rooted in the philosophies of functional medicine.
  • This state-of-the-art medical facility embodies beauty and function, mirroring Dr. Golberg's medical philosophy, and will offer expanded services and capabilities to provide complete, patient-centered functional medicine and aesthetic services that treat the whole person.
  • He's embraced a concierge approach to medicine, which he credits with enabling him to build the trust in patient relationships needed to treat their most pressing symptoms.

ESO Releases 2024 EMS Index to Explore Key Trends and Measures Affecting EMS Agencies across the Country

Retrieved on: 
Thursday, April 25, 2024
Data Management, Health, Technology, Other Health, Software, General Health, Naloxone, EMS, Hospital, Analgesic, Attention, Documentation, Cardiac arrest, Pain management, Patient, Opioid overdose, Record, ESO, Multimedia, Public health surveillance, Emergency medical services, CPR, Dentistry

ESO , a leading data and software company serving emergency medical services (EMS), fire departments, hospitals, state and federal agencies, today announced the findings of its 2024 EMS Index.

Key Points: 
  • ESO , a leading data and software company serving emergency medical services (EMS), fire departments, hospitals, state and federal agencies, today announced the findings of its 2024 EMS Index.
  • (Photo: Business Wire)
    "Since launching our first ESO EMS Index, we've seen how EMS agencies are using data to make meaningful and deliberate decisions that have a positive impact," said Dr. Brent Myers, Chief Medical Officer at ESO.
  • "This year, we've introduced several pivotal measures that are impacting the EMS industry, such as patient offload time, commonly known as 'wall time.'
  • This tells us that agencies should consider identifying communities with low rates of bystander CPR and provide outreach in those areas.”